Share Price and Basic Stock Data
Last Updated: March 8, 2025, 10:42 am
| PEG Ratio | 20.34 |
|---|
Competitors of Syncom Formulations (India) Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| MPS Pharmaa Ltd | 6.71 Cr. | 3.51 | 4.33/3.05 | 0.80 | 0.00 % | 9.15 % | 34.9 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 2,663 Cr. | 244 | 390/192 | 50.6 | 20.5 | 0.27 % | 45.0 % | 33.8 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 53.1 Cr. | 71.5 | 94.9/32.1 | 18.0 | 11.9 | 0.00 % | 9.72 % | 3.44 % | 10.0 |
| Gujarat Inject (Kerala) Ltd | 38.0 Cr. | 26.0 | 29.0/8.74 | 38.8 | 6.64 | 0.00 % | 2.65 % | 2.08 % | 10.0 |
| Godavari Drugs Ltd | 70.4 Cr. | 93.5 | 155/79.0 | 11.4 | 55.4 | 0.00 % | 14.4 % | 15.5 % | 10.0 |
| Industry Average | 17,255.37 Cr | 1,081.84 | 42.42 | 185.80 | 0.37% | 16.00% | 16.32% | 6.27 |
Quarterly Result
| Metric | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 57 | 58 | 51 | 54 | 57 | 61 | 59 | 62 | 63 | 73 | 86 | 101 | 127 |
| Expenses | 52 | 56 | 48 | 50 | 51 | 55 | 53 | 56 | 57 | 64 | 76 | 90 | 112 |
| Operating Profit | 5 | 2 | 3 | 4 | 6 | 6 | 6 | 6 | 7 | 9 | 10 | 12 | 15 |
| OPM % | 9% | 4% | 7% | 8% | 10% | 10% | 10% | 10% | 11% | 12% | 11% | 12% | 11% |
| Other Income | 2 | 6 | 3 | 3 | 2 | 7 | 2 | 4 | 4 | 3 | 2 | 4 | 4 |
| Interest | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 6 | 6 | 5 | 5 | 6 | 10 | 6 | 8 | 9 | 9 | 10 | 15 | 17 |
| Tax % | 33% | 16% | 22% | 33% | 30% | 18% | 27% | 24% | 25% | 27% | 24% | 25% | 24% |
| Net Profit | 4 | 5 | 4 | 4 | 4 | 8 | 4 | 6 | 6 | 7 | 8 | 11 | 13 |
| EPS in Rs | 0.05 | 0.06 | 0.04 | 0.04 | 0.04 | 0.09 | 0.05 | 0.07 | 0.07 | 0.07 | 0.08 | 0.12 | 0.14 |
Last Updated: February 28, 2025, 4:48 pm
Below is a detailed analysis of the quarterly data for Syncom Formulations (India) Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:
- For Sales, as of Dec 2024, the value is ₹127.00 Cr.. The value appears strong and on an upward trend. It has increased from 101.00 Cr. (Sep 2024) to ₹127.00 Cr., marking an increase of ₹26.00 Cr..
- For Expenses, as of Dec 2024, the value is ₹112.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 90.00 Cr. (Sep 2024) to ₹112.00 Cr., marking an increase of ₹22.00 Cr..
- For Operating Profit, as of Dec 2024, the value is ₹15.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Sep 2024) to ₹15.00 Cr., marking an increase of ₹3.00 Cr..
- For OPM %, as of Dec 2024, the value is 11.00%. The value appears to be declining and may need further review. It has decreased from 12.00% (Sep 2024) to 11.00%, marking a decrease of 1.00%.
- For Other Income, as of Dec 2024, the value is ₹4.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 4.00 Cr..
- For Interest, as of Dec 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
- For Depreciation, as of Dec 2024, the value is ₹1.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 1.00 Cr..
- For Profit before tax, as of Dec 2024, the value is ₹17.00 Cr.. The value appears strong and on an upward trend. It has increased from 15.00 Cr. (Sep 2024) to ₹17.00 Cr., marking an increase of ₹2.00 Cr..
- For Tax %, as of Dec 2024, the value is 24.00%. The value appears to be improving (decreasing) as expected. It has decreased from 25.00% (Sep 2024) to 24.00%, marking a decrease of 1.00%.
- For Net Profit, as of Dec 2024, the value is ₹13.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Sep 2024) to ₹13.00 Cr., marking an increase of ₹2.00 Cr..
- For EPS in Rs, as of Dec 2024, the value is 0.14. The value appears strong and on an upward trend. It has increased from ₹0.12 (Sep 2024) to 0.14, marking an increase of ₹0.02.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: March 7, 2025, 6:39 pm
| Metric | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 115 | 151 | 173 | 184 | 185 | 159 | 187 | 206 | 245 | 216 | 222 | 257 | 388 |
| Expenses | 104 | 135 | 155 | 167 | 168 | 147 | 175 | 189 | 207 | 196 | 202 | 229 | 343 |
| Operating Profit | 11 | 16 | 18 | 17 | 16 | 12 | 12 | 17 | 38 | 20 | 20 | 28 | 45 |
| OPM % | 9% | 11% | 11% | 9% | 9% | 7% | 6% | 8% | 16% | 9% | 9% | 11% | 12% |
| Other Income | 1 | 1 | 1 | 3 | 3 | 4 | 5 | 5 | 7 | 12 | 15 | 13 | 13 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 3 | 5 | 2 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 |
| Profit before tax | 8 | 14 | 16 | 16 | 16 | 12 | 13 | 17 | 41 | 26 | 27 | 32 | 51 |
| Tax % | 33% | 33% | 38% | 36% | 33% | 28% | 12% | 18% | 28% | 24% | 24% | 26% | |
| Net Profit | 6 | 9 | 10 | 10 | 11 | 9 | 11 | 14 | 29 | 20 | 20 | 24 | 38 |
| EPS in Rs | 0.07 | 0.12 | 0.13 | 0.13 | 0.14 | 0.11 | 0.14 | 0.18 | 0.37 | 0.23 | 0.21 | 0.25 | 0.41 |
| Dividend Payout % | 24% | 17% | 16% | 15% | 15% | 0% | 0% | 0% | 0% | 13% | 0% | 0% |
YoY Net Profit Growth
| Year | 2013-2014 | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 50.00% | 11.11% | 0.00% | 10.00% | -18.18% | 22.22% | 27.27% | 107.14% | -31.03% | 0.00% | 20.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -38.89% | -11.11% | 10.00% | -28.18% | 40.40% | 5.05% | 79.87% | -138.18% | 31.03% | 20.00% |
Syncom Formulations (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: December 14, 2024, 2:39 pm
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 78 | 78 | 78 | 78 | 78 | 78 | 78 | 79 | 86 | 94 | 94 | 94 |
| Reserves | 65 | 17 | 22 | 31 | 36 | 44 | 55 | 68 | 109 | 136 | 162 | 192 | 218 |
| Borrowings | 2 | 3 | 6 | 6 | 12 | 12 | 9 | 2 | 62 | 58 | 83 | 72 | 14 |
| Other Liabilities | 33 | 42 | 31 | 61 | 48 | 37 | 32 | 33 | 42 | 28 | 38 | 33 | 44 |
| Total Liabilities | 123 | 140 | 138 | 175 | 175 | 171 | 173 | 181 | 292 | 308 | 377 | 392 | 369 |
| Fixed Assets | 50 | 50 | 46 | 46 | 85 | 89 | 89 | 93 | 91 | 94 | 91 | 120 | 117 |
| CWIP | 0 | 0 | 0 | 5 | 0 | 1 | 0 | 0 | 0 | 6 | 26 | 0 | 1 |
| Investments | 7 | 9 | 6 | 23 | 1 | 2 | 2 | 1 | 11 | 43 | 64 | 66 | 86 |
| Other Assets | 66 | 80 | 85 | 101 | 89 | 79 | 83 | 87 | 189 | 165 | 196 | 206 | 165 |
| Total Assets | 123 | 140 | 138 | 175 | 175 | 171 | 173 | 181 | 292 | 308 | 377 | 392 | 369 |
Below is a detailed analysis of the balance sheet data for Syncom Formulations (India) Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2024, the value is ₹94.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹94.00 Cr..
- For Reserves, as of Sep 2024, the value is ₹218.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹192.00 Cr. (Mar 2024) to ₹218.00 Cr., marking an increase of 26.00 Cr..
- For Borrowings, as of Sep 2024, the value is ₹14.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from ₹72.00 Cr. (Mar 2024) to ₹14.00 Cr., marking a decrease of 58.00 Cr..
- For Other Liabilities, as of Sep 2024, the value is ₹44.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹33.00 Cr. (Mar 2024) to ₹44.00 Cr., marking an increase of 11.00 Cr..
- For Total Liabilities, as of Sep 2024, the value is ₹369.00 Cr.. The value appears to be improving (decreasing). It has decreased from ₹392.00 Cr. (Mar 2024) to ₹369.00 Cr., marking a decrease of 23.00 Cr..
- For Fixed Assets, as of Sep 2024, the value is ₹117.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹120.00 Cr. (Mar 2024) to ₹117.00 Cr., marking a decrease of 3.00 Cr..
- For CWIP, as of Sep 2024, the value is ₹1.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹0.00 Cr. (Mar 2024) to ₹1.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Sep 2024, the value is ₹86.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹66.00 Cr. (Mar 2024) to ₹86.00 Cr., marking an increase of 20.00 Cr..
- For Other Assets, as of Sep 2024, the value is ₹165.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹206.00 Cr. (Mar 2024) to ₹165.00 Cr., marking a decrease of 41.00 Cr..
- For Total Assets, as of Sep 2024, the value is ₹369.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹392.00 Cr. (Mar 2024) to ₹369.00 Cr., marking a decrease of 23.00 Cr..
Notably, the Reserves (₹218.00 Cr.) exceed the Borrowings (14.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
No data available for this post.
Free Cash Flow
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 9.00 | 13.00 | 12.00 | 11.00 | 4.00 | 0.00 | 3.00 | 15.00 | -24.00 | -38.00 | -63.00 | -44.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 92 | 71 | 66 | 91 | 91 | 87 | 81 | 77 | 112 | 114 | 124 | 132 |
| Inventory Days | 29 | 36 | 34 | 43 | 29 | 37 | 37 | 39 | 51 | 51 | 53 | 49 |
| Days Payable | 91 | 105 | 63 | 130 | 92 | 75 | 57 | 49 | 66 | 36 | 52 | 33 |
| Cash Conversion Cycle | 29 | 1 | 37 | 4 | 27 | 49 | 61 | 67 | 96 | 129 | 124 | 148 |
| Working Capital Days | 101 | 83 | 97 | 51 | 70 | 103 | 90 | 92 | 121 | 131 | 133 | 153 |
| ROCE % | 10% | 15% | 16% | 15% | 14% | 9% | 9% | 12% | 21% | 11% | 10% | 10% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 5,387 | 0.09 | 0.01 | 5,387 | 2025-03-06 | 0% |
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 17 | Mar 16 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 0.34 | 0.24 | 0.26 | 0.13 | 0.13 |
| Diluted EPS (Rs.) | 0.34 | 0.24 | 0.24 | 0.13 | 0.13 |
| Cash EPS (Rs.) | 0.31 | 0.26 | 0.27 | 0.17 | 0.17 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 3.07 | 2.72 | 2.58 | 1.50 | 1.39 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 3.07 | 2.72 | 2.58 | 1.50 | 1.39 |
| Revenue From Operations / Share (Rs.) | 2.80 | 2.39 | 2.55 | 2.37 | 2.36 |
| PBDIT / Share (Rs.) | 0.45 | 0.36 | 0.37 | 0.24 | 0.24 |
| PBIT / Share (Rs.) | 0.40 | 0.31 | 0.32 | 0.20 | 0.20 |
| PBT / Share (Rs.) | 0.36 | 0.28 | 0.30 | 0.20 | 0.20 |
| Net Profit / Share (Rs.) | 0.26 | 0.21 | 0.22 | 0.13 | 0.13 |
| NP After MI And SOA / Share (Rs.) | 0.26 | 0.21 | 0.22 | 0.13 | 0.13 |
| PBDIT Margin (%) | 16.39 | 15.26 | 14.58 | 10.43 | 10.47 |
| PBIT Margin (%) | 14.59 | 13.23 | 12.78 | 8.74 | 8.84 |
| PBT Margin (%) | 12.89 | 11.84 | 11.91 | 8.59 | 8.81 |
| Net Profit Margin (%) | 9.61 | 8.94 | 9.00 | 5.69 | 5.63 |
| NP After MI And SOA Margin (%) | 9.61 | 8.94 | 9.00 | 5.69 | 5.63 |
| Return on Networth / Equity (%) | 8.78 | 7.83 | 8.90 | 8.97 | 9.52 |
| Return on Capital Employeed (%) | 12.89 | 11.21 | 12.20 | 12.92 | 14.15 |
| Return On Assets (%) | 6.25 | 5.31 | 6.42 | 5.84 | 5.90 |
| Total Debt / Equity (X) | 0.25 | 0.32 | 0.26 | 0.10 | 0.05 |
| Asset Turnover Ratio (%) | 0.67 | 0.65 | 0.00 | 1.05 | 1.18 |
| Current Ratio (X) | 2.58 | 1.61 | 1.79 | 1.50 | 1.43 |
| Quick Ratio (X) | 2.38 | 1.42 | 1.54 | 1.32 | 1.17 |
| Inventory Turnover Ratio (X) | 6.22 | 4.89 | 0.00 | 5.42 | 5.22 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 14.82 | 15.07 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 11.43 | 11.69 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 85.18 | 84.93 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 88.57 | 88.31 |
| Interest Coverage Ratio (X) | 9.65 | 10.93 | 16.62 | 68.46 | 271.98 |
| Interest Coverage Ratio (Post Tax) (X) | 6.66 | 7.41 | 11.25 | 38.42 | 148.59 |
| Enterprise Value (Cr.) | 1055.54 | 629.15 | 974.19 | 159.72 | 174.01 |
| EV / Net Operating Revenue (X) | 4.01 | 2.81 | 4.43 | 0.86 | 0.94 |
| EV / EBITDA (X) | 24.45 | 18.38 | 30.42 | 8.28 | 9.03 |
| MarketCap / Net Operating Revenue (X) | 3.99 | 2.47 | 4.17 | 0.83 | 0.94 |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 85.17 | 84.92 |
| Price / BV (X) | 3.65 | 2.17 | 4.13 | 1.31 | 1.60 |
| Price / Net Operating Revenue (X) | 3.99 | 2.47 | 4.17 | 0.83 | 0.94 |
| EarningsYield | 0.02 | 0.03 | 0.02 | 0.06 | 0.05 |
After reviewing the key financial ratios for Syncom Formulations (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 0.34. This value is below the healthy minimum of 5. It has increased from 0.24 (Mar 23) to 0.34, marking an increase of 0.10.
- For Diluted EPS (Rs.), as of Mar 24, the value is 0.34. This value is below the healthy minimum of 5. It has increased from 0.24 (Mar 23) to 0.34, marking an increase of 0.10.
- For Cash EPS (Rs.), as of Mar 24, the value is 0.31. This value is below the healthy minimum of 3. It has increased from 0.26 (Mar 23) to 0.31, marking an increase of 0.05.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 3.07. It has increased from 2.72 (Mar 23) to 3.07, marking an increase of 0.35.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 3.07. It has increased from 2.72 (Mar 23) to 3.07, marking an increase of 0.35.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 2.80. It has increased from 2.39 (Mar 23) to 2.80, marking an increase of 0.41.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 0.45. This value is below the healthy minimum of 2. It has increased from 0.36 (Mar 23) to 0.45, marking an increase of 0.09.
- For PBIT / Share (Rs.), as of Mar 24, the value is 0.40. This value is within the healthy range. It has increased from 0.31 (Mar 23) to 0.40, marking an increase of 0.09.
- For PBT / Share (Rs.), as of Mar 24, the value is 0.36. This value is within the healthy range. It has increased from 0.28 (Mar 23) to 0.36, marking an increase of 0.08.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 0.26. This value is below the healthy minimum of 2. It has increased from 0.21 (Mar 23) to 0.26, marking an increase of 0.05.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 0.26. This value is below the healthy minimum of 2. It has increased from 0.21 (Mar 23) to 0.26, marking an increase of 0.05.
- For PBDIT Margin (%), as of Mar 24, the value is 16.39. This value is within the healthy range. It has increased from 15.26 (Mar 23) to 16.39, marking an increase of 1.13.
- For PBIT Margin (%), as of Mar 24, the value is 14.59. This value is within the healthy range. It has increased from 13.23 (Mar 23) to 14.59, marking an increase of 1.36.
- For PBT Margin (%), as of Mar 24, the value is 12.89. This value is within the healthy range. It has increased from 11.84 (Mar 23) to 12.89, marking an increase of 1.05.
- For Net Profit Margin (%), as of Mar 24, the value is 9.61. This value is within the healthy range. It has increased from 8.94 (Mar 23) to 9.61, marking an increase of 0.67.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is 9.61. This value is within the healthy range. It has increased from 8.94 (Mar 23) to 9.61, marking an increase of 0.67.
- For Return on Networth / Equity (%), as of Mar 24, the value is 8.78. This value is below the healthy minimum of 15. It has increased from 7.83 (Mar 23) to 8.78, marking an increase of 0.95.
- For Return on Capital Employeed (%), as of Mar 24, the value is 12.89. This value is within the healthy range. It has increased from 11.21 (Mar 23) to 12.89, marking an increase of 1.68.
- For Return On Assets (%), as of Mar 24, the value is 6.25. This value is within the healthy range. It has increased from 5.31 (Mar 23) to 6.25, marking an increase of 0.94.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.25. This value is within the healthy range. It has decreased from 0.32 (Mar 23) to 0.25, marking a decrease of 0.07.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.67. It has increased from 0.65 (Mar 23) to 0.67, marking an increase of 0.02.
- For Current Ratio (X), as of Mar 24, the value is 2.58. This value is within the healthy range. It has increased from 1.61 (Mar 23) to 2.58, marking an increase of 0.97.
- For Quick Ratio (X), as of Mar 24, the value is 2.38. This value exceeds the healthy maximum of 2. It has increased from 1.42 (Mar 23) to 2.38, marking an increase of 0.96.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 6.22. This value is within the healthy range. It has increased from 4.89 (Mar 23) to 6.22, marking an increase of 1.33.
- For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 9.65. This value is within the healthy range. It has decreased from 10.93 (Mar 23) to 9.65, marking a decrease of 1.28.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 6.66. This value is within the healthy range. It has decreased from 7.41 (Mar 23) to 6.66, marking a decrease of 0.75.
- For Enterprise Value (Cr.), as of Mar 24, the value is 1,055.54. It has increased from 629.15 (Mar 23) to 1,055.54, marking an increase of 426.39.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 4.01. This value exceeds the healthy maximum of 3. It has increased from 2.81 (Mar 23) to 4.01, marking an increase of 1.20.
- For EV / EBITDA (X), as of Mar 24, the value is 24.45. This value exceeds the healthy maximum of 15. It has increased from 18.38 (Mar 23) to 24.45, marking an increase of 6.07.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 3.99. This value exceeds the healthy maximum of 3. It has increased from 2.47 (Mar 23) to 3.99, marking an increase of 1.52.
- For Retention Ratios (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Price / BV (X), as of Mar 24, the value is 3.65. This value exceeds the healthy maximum of 3. It has increased from 2.17 (Mar 23) to 3.65, marking an increase of 1.48.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 3.99. This value exceeds the healthy maximum of 3. It has increased from 2.47 (Mar 23) to 3.99, marking an increase of 1.52.
- For EarningsYield, as of Mar 24, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 23) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Syncom Formulations (India) Ltd:
- Net Profit Margin: 9.61%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 12.89% (Industry Average ROCE: 16%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.78% (Industry Average ROE: 16.32%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 6.66
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.38
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 42.2 (Industry average Stock P/E: 42.42)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.25
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.61%
About the Company - Qualitative Analysis
Syncom Formulation (India) Ltd. is a Public Limited Listed company incorporated on 21/06/1988 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24239MH1988PLC047759 and registration number is 047759. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 258.36 Cr. and Equity Capital is Rs. 94.00 Cr. for the Year ended 31/03/2024.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 7, Niraj Industrial Estate, Mumbai Maharashtra 400093 | finance@sfil.in http://www.sfil.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Kedarmal Shankarlal Bankda | Exe.Chairman & W T D |
| Mr. Vijay Shankarlal Bankda | Managing Director |
| Mrs. Rinki Ankit Bankda | Whole Time Director |
| Mrs. Ruchi Jindal | Independent Woman Director |
| Mr. Ritesh Kumar Lunkad | Independent Director |
| Mr. Ankit Jain | Independent Director |
FAQ
What is the latest intrinsic value of Syncom Formulations (India) Ltd?
The latest intrinsic value of Syncom Formulations (India) Ltd as on 12 March 2025 is ₹9.73, which is 43.10% lower than the current market price of 17.10, indicating the stock is overvalued by 43.10%. The intrinsic value of Syncom Formulations (India) Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹1,608 Cr. and recorded a high/low of ₹27.9/11.0 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹218 Cr and total liabilities of ₹369 Cr.
What is the Market Cap of Syncom Formulations (India) Ltd?
The Market Cap of Syncom Formulations (India) Ltd is 1,608 Cr..
What is the current Stock Price of Syncom Formulations (India) Ltd as on 12 March 2025?
The current stock price of Syncom Formulations (India) Ltd as on 12 March 2025 is ₹17.1.
What is the High / Low of Syncom Formulations (India) Ltd stocks in FY 2024-2025?
In FY 2024-2025, the High / Low of Syncom Formulations (India) Ltd stocks is ₹27.9/11.0.
What is the Stock P/E of Syncom Formulations (India) Ltd?
The Stock P/E of Syncom Formulations (India) Ltd is 42.2.
What is the Book Value of Syncom Formulations (India) Ltd?
The Book Value of Syncom Formulations (India) Ltd is 3.32.
What is the Dividend Yield of Syncom Formulations (India) Ltd?
The Dividend Yield of Syncom Formulations (India) Ltd is 0.00 %.
What is the ROCE of Syncom Formulations (India) Ltd?
The ROCE of Syncom Formulations (India) Ltd is 10.2 %.
What is the ROE of Syncom Formulations (India) Ltd?
The ROE of Syncom Formulations (India) Ltd is 8.51 %.
What is the Face Value of Syncom Formulations (India) Ltd?
The Face Value of Syncom Formulations (India) Ltd is 1.00.